Enzene appoints Norm Stoffregen to lead new U.S. biomanufacturing facility

New Delhi: Enzene Biosciences has appointed Norm Stoffregen as Senior Vice President, site head, and head of biologics manufacturing at its new $50 million continuous manufacturing facility in Hopewell, New Jersey. Stoffregen will oversee the final stages of commissioning the 54,000-square-foot facility and lead its operations as Enzene expands its biologics manufacturing capabilities in the U.S.

The Hopewell site, located near Princeton, will serve as a key hub in Enzene’s global network, supporting the company’s vision to lower the cost of biologics production and improve manufacturing processes. The facility will also incorporate EnzeneX™, the company’s advanced continuous manufacturing platform, along with state-of-the-art development and quality laboratories, warehousing, frozen storage, and cell banking.

Stoffregen, who brings over 20 years of experience in the biomanufacturing industry, will also lead Enzene’s global biologics business. His expertise is expected to be instrumental in expanding the facility’s capabilities and transferring in existing customer projects. By the end of 2025, the site aims to employ 300 staff and expand its bioreactor capacity. Stoffregen’s familiarity with the Hopewell facility, having worked there since 2015 during its ownership by Bristol Myers Squibb, adds significant value to his leadership role.

“I am delighted to welcome Norman to Enzene,” said Himanshu Gadgil, CEO of Enzene Biosciences. “His knowledge of the facility, our colleagues, customers and suppliers will be invaluable as we develop our customer base and expand operations, further building our reputation as a world class biologics innovator dedicated to lowering the cost of biologics production, and continually improving manufacturing techniques.”

Stoffregen expressed, “Existing and new customers see the powerful opportunities that continuous biologics technology brings, not least by providing flexibility and lowering the cost of manufacturing. We are already in discussion with biopharma companies keen to progress programs for the domestic market and beyond, and in the next 18-months we expect to ramp up our production capacity and capabilities, and grow our pipeline of work with biotech and pharma companies in early phases of development.”

Before joining Enzene, Stoffregen served as VP-site head at PTC Therapeutics. He has held various leadership roles at Bristol Myers Squibb and other bioprocessing companies. Stoffregen holds a bachelor’s degree from the State University of New York at New Paltz.

Enzene’s expansion into the U.S. marks a critical step in the company’s global growth strategy, as it leverages its continuous manufacturing expertise developed at its Pune, India facility.